Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.METABOL.2005.06.021PMID 16324915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  2005cited by this paper
• Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin.

  2005cited by this paper
• Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study

  2005cited by this paper
• Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.

  2005cited by this paper
• Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome

  2005cited by this paper
• Significant association of insulin and proinsulin with clustering of cardiovascular risk factors.

  2005cited by this paper
• Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

  2004cited by this paper
• The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

  2004cited by this paper
• Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages.

  2004cited by this paper
• Increased oxidative stress in obesity and its impact on metabolic syndrome.

  2004cited by this paper
• Adiponectin and its role in the obesity-induced insulin resistance and related complications.

  2004cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.

  2004cited by this paper
• Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3‐L1 adipocytes

  2004cited by this paper
• Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus

  2004cited by this paper
• C‐reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones

  2004cited by this paper
• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial

  2004cited by this paper
• Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.

  2004cited by this paper
• [Cardiovascular effects of rosiglitazone].

  2004cited by this paper
• Evidence for a potent antiinflammatory effect of rosiglitazone.

  2004cited by this paper
• Adiponectin as a biomarker of the metabolic syndrome.

  2004cited by this paper
• Effets cardiovasculaires de la rosiglitazone

  2004cited by this paper
• Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase

  2003cited by this paper
• The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.

  2003cited by this paper
• Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices.

  2003cited by this paper
• Thiazolidinediones – some recent developments

  2003cited by this paper
• Rosiglitazone (PPARγ‐agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes–atherosclerosis mouse model

  2003cited by this paper
• Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

  2003cited by this paper
• Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women.

  2002cited by this paper
• Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.

  2002cited by this paper
• Increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes.

  2002cited by this paper
• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  2002cited by this paper
• Sex Differences in the Association Between Proinsulin and Intact Insulin With Coronary Heart Disease in Nondiabetic Older Adults: The Rancho Bernardo Study

  2002cited by this paper
• Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

  2002cited by this paper
• Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects?

  2002cited by this paper
• PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

  2001cited by this paper
• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

  2001cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• Relation between insulin resistance and carotid intima‐media thickness and stenosis in non‐diabetic subjects. Results from a cross‐sectional study in Malmö, Sweden

  2000cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

  1998cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

  1998cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2563–2568 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2004-0518 Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function

  year unknowncited by this paper

• Impact of a Cinnamon Extract Vs. Placebo on Metabolic Control in Patients with Type 2 Diabetes Mellitus

  2021cites this paper
• The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes.

  2019cites this paper
• The Physical Burden of Immunoperception

  2019cites this paper
• Delir beim Intensivpatienten

  2019cites this paper
• Delir beim Intensivpatienten

  2019cites this paper
• Delir beim Intensivpatienten

  2018cites this paper
• Childhood abuse and depression in adulthood: The mediating role of allostatic load.

  2018cites this paper
• Reduced Theta Coherence and P Wave Ratio Linked to Memory Deficits After Sleep Deprivation in Rat Model

  2017cites this paper
• Identification of Highly Specific scFvs against Total Adiponectin for Diagnostic Purposes

  2017cites this paper
• Evaluation of ADMA, carbonyl groups, CAT and NKA in depressed patients with and without posttraumatic stress disorder

  2017cites this paper
• How Does Work Fit with My Life? The Relation Between Flexible Work Arrangements, Work–Life Balance and Recovery from Work

  2017cites this paper
• Cdkal1, a type 2 diabetes susceptibility gene, regulates mitochondrial function in adipose tissue

  2017cites this paper
• Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.

  2016cites this paper
• Emotional Security Theory and Developmental Psychopathology

  2016cites this paper
• Homobimetallic zinc(II) dithiocarbamates: synthesis, characterization and in vivo antihyperglycemic activity

  2016cites this paper
• Effects of commonly used antidiabetic drugs on antioxidant enzymes and liver function test markers in type 2 diabetes mellitus subjects - pilot study.

  2015cites this paper
• Amelioration of the Possible Adverse Effects of Rosiglitazone by Fenugreek and Vitamin E in STZ-induced Diabetes in Rats

  2015cites this paper
• Antidiabetic, antihyperlipidemic and histopathological analysis of Cleome droserifolia methanolic extract on alloxan induced diabetic rats

  2015cites this paper
• Antidiabetic, antihyperlipidemic and histopathological analysis of Panax quinquefolium extract on alloxan induced diabetic rats

  2015cites this paper
• Relationships Among Nightly Sleep Quality, Daily Stress, and Daily Affect

  2015cites this paper
• Biochemical and histopathological analysis of Cystoseira myrica aqueous extract on alloxan induced diabetic rats

  2015cites this paper
• Biochemical and histopathological analysis of Hydroclathrus clathratus aqueous extract on alloxan induced diabetic rats

  2015cites this paper
• Breaking the Mold: Transcription Factors in the Anucleate Platelet and Platelet-Derived Microparticles

  2015cites this paper
• Biochemical profiles and histopathological analysis of Cleome droserifolia methanolic extract on alloxan induced diabetic rats

  2015cites this paper
• Chronic sleep loss during pregnancy as a determinant of stress: impact on pregnancy outcome.

  2014cites this paper
• The genetics of insomnia--evidence for epigenetic mechanisms?

  2014cites this paper
• Adiposity and Kidney Disease

  2014cites this paper
• Metabolic Syndrome and associated pathologies

  2013cites this paper
• Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome

  2013cites this paper
• REM sleep dysregulation in depression: state of the art.

  2013cites this paper
• Stress e disturbi del sonno: Dagli aspetti neurobiologici alla clinica

  2012cites this paper
• Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature

  2012cites this paper
• The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact.

  2011cites this paper
• Rosiglitazone Maleate and Glimepiride in Fixed Combination for the Metabolic Control of Type 2 Diabetes

  2011cites this paper
• Elevated Intact Proinsulin Levels are Indicative of Beta-Cell Dysfunction, Insulin Resistance, and Cardiovascular Risk: Impact of the Antidiabetic Agent Pioglitazone

  2011cites this paper
• Synthesis, characterization and anti-diabetic effect of bis[(1-R-imidazolinyl)phenolato]oxovanadium(IV) complexes

  2010cites this paper
• PREDICTION OF PERSONAL HEALTH RISK FACTORS IN METABOLIC SYNDROME

  2010cites this paper
• Short sleeping time and psychobiological responses to acute stress.

  2010cites this paper
• Unobtrusive and Non-invasive Sensing Solutions for On-Line Physiological Parameters Monitoring

  2010cites this paper
• High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone

  2010cites this paper
• Limitations of the HOMA-B Score for Assessment of β-Cell Functionality in Interventional Trials—Results from the PIOglim study

  2010cites this paper
• Wczesne rozpoczęcie intensywnego leczenia insuliną u chorych na cukrzycę typu 2: dostępne dowody naukowe

  2009cites this paper
• Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus*

  2009cites this paper
• Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β‐cell function: results from the PioSwitch Study

  2009cites this paper
• Pleiotropic effects of thiazolidinediones on traditional and non‐traditional atherosclerotic risk factors

  2009cites this paper
• The backbone of oral glucose‐lowering therapy: time for a paradigm shift?

  2009cites this paper
• Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy.

  2009cites this paper
• Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?

  2009cites this paper
• Cardiovascular Manifestations of Insulin Resistance

  2009influential citation
• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2

  2009cites this paper
• ea rly and Aggressive in itiation of in sulin t h erapy for t y pe 2 Diabetes: What i s the ev idence?

  2009cites this paper
• Sleep and recovery

  2009cites this paper
• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ2 Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft Pharmacological Antihyperglycemic Therapy of Type2 Diabetes mellitus Update of the Evidence-Based Guidelines of the German Diabetes Association

  2009cites this paper
• Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non‐diabetic patients

  2008cites this paper
• Review Article: Adiponectin: Its role in kidney disease

  2008cites this paper
• Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes

  2008cites this paper
• Marker for the diagnosis of an insulin resistance

  2008cites this paper
• The effect of thiazolidinediones on adiponectin serum level: a meta‐analysis

  2008cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

  2008cites this paper
• A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus.

  2008cites this paper
• Clinical Use of a Combined Preparation Containing Rosiglitazone and Glimepiride in the Treatment of Type 2 Diabetes Mellitus

  2008cites this paper
• Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus

  2008cites this paper
• Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes

  2008cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

  2008cites this paper
• Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.

  2008cites this paper
• Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.

  2007cites this paper
• The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

  2007cites this paper
• Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

  2007cites this paper
• Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects

  2007cites this paper
• Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin‐18 is an independent factor for the improvement of homeostasis model assessment‐beta in type 2 diabetes mellitus

  2007cites this paper
• Review of the Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor γ Agonists on Platelet Function

  2007cites this paper
• [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].

  2007cites this paper
• Typ-2-Diabetes - Prävention und Progressionshemmung durch Glitazone

  2007cites this paper
• Long-term consumption of fermented soybean-derived Chungkookjang enhances insulinotropic action unlike soybeans in 90% pancreatectomized diabetic rats

  2007cites this paper
• Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.

  2007cites this paper
• Optimizing combination treatment in the management of type 2 diabetes

  2007cites this paper
• A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex.

  2007cites this paper
• Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study

  2007cites this paper
• Impact of Treatment with Rosiglitazone or Metformin on Biomarkers for Insulin Resistance and Metabolic Syndrome in Patients with Polycystic Ovary Syndrome

  2007cites this paper
• Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

  2006cites this paper
• High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus

  2006cites this paper
• Rosiglitazone is effective and well‐tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes

  2006cites this paper
• Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus

  2006cites this paper
• Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment

  2006cites this paper
• Ocena bezpieczeństwa i skuteczności stosowania preparatu AVANDIA (rosiglitazon) w leczeniu cukrzycy typu 2 - program ROSE

  2006cites this paper
• Peroxisome proliferator-activated receptor-γ and lipodystrophy

  2006cites this paper
• Can thiazolidinediones delay disease progression in type 2 diabetes?

  2006cites this paper
• Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

  2006cites this paper
• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

  2006cites this paper
• Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus

  2004cites this paper